即刻植入物乳房再造中阿片类药物消耗的预测因素
前瞻性队列研究纳入100例即刻植入物乳房再造患者,术后平均处方36.0片5mg羟考酮,实际消耗20.6片(57.0%),28.2%患者未使用阿片类药物。术前阿片使用、住院期间阿片消耗及疼痛控制相关焦虑是阿片消耗的预测因素。
要点
- 术后阿片处方量约为实际消耗量的近两倍,28.2%患者未使用。
- 术前阿片使用、住院阿片消耗和疼痛焦虑预测术后阿片消耗。
- 临床因素可指导个体化阿片处方实践。
核心结论
- 乳房切除及植入物乳房再造患者获处方阿片片数近实际消耗两倍,三分之一患者术后未用阿片。
- 临床因素可帮助指导处方实践。
研究设计与样本
- 前瞻性队列调查研究,纳入100例即刻植入物乳房再造咨询患者,术前和术后问卷收集疼痛预期和阿片使用,并行病历回顾。
主要发现
- 97例(97.0%)接受手术,85例(85.0%)完成术后问卷。
- 术前27例(27.0%)有慢性疼痛综合征史,34例(34.0%)有精神健康共病史,9例(9.0%)有术前阿片使用史。
- 完成85例(87.6%)组织扩张器和12例(12.4%)直接植入再造。
- 平均处方36.0片5mg羟考酮,患者报告平均消耗20.6片,占处方量57.0%。
- 75.3%患者调查时每日使用阿片少于一次,24例(28.2%)术后未用任何阿片。
关键数值与推荐
- 术前阿片使用(p=0.004)、住院阿片消耗(p<0.0001)和患者报告的疼痛控制相关焦虑(p<0.05)是阿片消耗的预测因素。
- 证据等级:风险,III级。
临床怎么用
- 可利用术前阿片使用史、住院阿片消耗和疼痛焦虑识别高消耗风险患者,优化处方量。
- 避免常规过量处方,结合患者因素个体化调整阿片处方。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current rates of opioid prescribing have deleterious consequences on both patient and societal levels. This study aims to evaluate responsible opioid prescribing and predictors of opioid consumption in immediate implant-based breast reconstruction. METHODS: Patients undergoing consultation for immediate, implant-based breast reconstruction were enrolled in a prospective, cohort survey study. A survey was administered at the preoperative and postoperative appointment to collect data on pain expectations and opioid use. A medical record review was performed. RESULTS: Of 100 enrolled patients, 97 (97.0 percent) underwent surgery and 85 (85.0 percent) completed the postoperative survey. Preoperatively, 27 patients (27.0 percent) had a history of a chronic pain syndrome, 34 (34.0 percent) had a history of a mental health comorbidity, and nine (9.0 percent) had a history of active preoperative opioid use. A total of 85 tissue expander (87.6 percent) and 12 direct-to-implant (12.4 percent) reconstructions were completed. Patients were prescribed an average of 36.0 5-mg oxycodone tablets postoperatively. Patients reported consuming an average of 20.6 tablets, or 57.0 percent of the average prescription amount. The majority of patients (75.3 percent) reported taking an opioid less than once per day at the time of survey completion, and 24 patients (28.2 percent) reported that they did not use any opioids postoperatively. Preoperative opioid use (p = 0.004), inpatient opioid consumption (p < 0.0001), and patient-reported anxiety related to pain control (p < 0.05) were predictors of opioid consumption. CONCLUSIONS: Patients undergoing mastectomy and implant-based breast reconstruction are prescribed nearly twice as many opioid tablets as consumed, and one in three patients report not using any opioids postoperatively. Clinical factors may help guide prescribing practices. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.
引用
- Egan KG, De Souza M, Muenks E, et al. Predictors of Opioid Consumption in Immediate, Implant-Based Breast Reconstruction. Plast Reconstr Surg. 2020. PMID: 32969995. doi:10.1097/PRS.0000000000007150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。